Viva Biotech Holdings (01873.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 1.40

From 52W high−55.20%

Volume8.20M

Market capHKD 3.09B

P/E (TTM)15.3x

P/S (TTM)1.4x

Div yield—

Key dataSep 18, 2026

Open

HKD 1.40

From 52W high

−55.20%

Volume

8.20M

Market cap

HKD 3.09B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

6.5x

P/E (TTM)

15.3x

RSI (14)

57.6

MomentumView details →

1D Return

+5.02%

YTD Return

−18.61%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

15.3x

EV/EBITDA

6.5x

EV/Sales

1.3x

P/S (TTM)

1.4x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

34.55%

Net Margin

9.36%

EBITDA Margin

20.23%

ROE (TTM)

4.47%

ROA (TTM)

2.57%

Asset Turnover

0.27x

GrowthView details →

Revenue YoY

+2.91%

EPS YoY

+0.86%

FCF YoY

+32.78%

Revenue CAGR 3Y

−10.09%

EPS CAGR 3Y

+14.94%

EBITDA YoY

−10.50%

MomentumView details →

1D Return

+5.02%

YTD Return

−18.61%

1Y Return

−43.22%

RSI (14)

57.6

vs 50D SMA

+6.37%

vs 200D SMA

−14.26%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

1.52x

Quick Ratio

1.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

−68.75%

EarningsView details →

EPS (Actual)

HKD 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

1.28%

Financials snapshotView financials →

Revenue (TTM)

3.73B

Net Income (TTM)

349.22M

Op. CF (TTM)

778.84M

Next earningsApr 1, 2027 →

Latest newsMore news →

Viva Biotech Holdings announced its interim results for the six months ended June 2026, with revenue of RMB 1.007 billion, up 21% year-on-year, and net profit of RMB 80.08 million, down 34.3%.25d ago

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.32d ago

Similar companies

凯因科技688687.SH HJ Science Co., Ltd.06132.HK 南模生物688265.SH uniQure N.V.QURE 蔚蓝生物603739.SH Jiangsu Recbio Technology Co., Ltd.02179.HK Find similar companies →

Latest newsMore news →

Viva Biotech Holdings announced its interim results for the six months ended June 2026, with revenue of RMB 1.007 billion, up 21% year-on-year, and net profit of RMB 80.08 million, down 34.3%.25d ago On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.32d ago